Beyond KRAS mutation status: influence of KRAScopy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Beyond KRAS mutation status: influence of KRAScopy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients ; volume:12 ; number:1 ; day:17 ; month:7 ; year:2012 ; pages:1-11 ; date:12.2012
BMC cancer ; 12, Heft 1 (17.7.2012), 1-11, 12.2012
- Creator
-
Mekenkamp, Leonie JM
- Contributor
-
Tol, Jolien
Dijkstra, Jeroen R.
de Krijger, Inge
Vink-Börger, M Elisa
van Vliet, Shannon
Teerenstra, Steven
Kamping, Eveline
Verwiel, Eugène
Koopman, Miriam
Meijer, Gerrit A.
van Krieken, J Han JM
Kuiper, Roland
Punt, Cornelis JA
Nagtegaal, Iris D.
SpringerLink (Online service)
- DOI
-
10.1186/1471-2407-12-292
- URN
-
urn:nbn:de:1111-20160304984
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:37 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Mekenkamp, Leonie JM
- Tol, Jolien
- Dijkstra, Jeroen R.
- de Krijger, Inge
- Vink-Börger, M Elisa
- van Vliet, Shannon
- Teerenstra, Steven
- Kamping, Eveline
- Verwiel, Eugène
- Koopman, Miriam
- Meijer, Gerrit A.
- van Krieken, J Han JM
- Kuiper, Roland
- Punt, Cornelis JA
- Nagtegaal, Iris D.
- SpringerLink (Online service)
Other Objects (12)
Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer
Randomized phase II study of cetuximab versus irinotecan and cetuximab in patients with chemo-refractory KRAS codon G13D metastatic colorectal cancer (G13D-study)
EGFR related mutational status and association to clinical outcome of third-line cetuximab-irinotecan in metastatic colorectal cancer
Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer
KRAS Status is Associated with Metabolic Parameters in Metastatic Colorectal Cancer According to Primary Tumour Location
Concordance of KRAS/BRAF Mutation Status in Metastatic Colorectal Cancer before and after Anti-EGFR Therapy
Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan
KRAS induces lung tumorigenesis through microRNAs modulation
Author Correction: Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer
Characterizing MRI features of rectal cancers with different KRAS status
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial
KRAS and BRAF mutational status in colon cancer from Albanian patients
Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer
Randomized phase II study of cetuximab versus irinotecan and cetuximab in patients with chemo-refractory KRAS codon G13D metastatic colorectal cancer (G13D-study)
EGFR related mutational status and association to clinical outcome of third-line cetuximab-irinotecan in metastatic colorectal cancer
Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer
KRAS Status is Associated with Metabolic Parameters in Metastatic Colorectal Cancer According to Primary Tumour Location
Concordance of KRAS/BRAF Mutation Status in Metastatic Colorectal Cancer before and after Anti-EGFR Therapy
Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan
KRAS induces lung tumorigenesis through microRNAs modulation
Author Correction: Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer
Characterizing MRI features of rectal cancers with different KRAS status
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial
KRAS and BRAF mutational status in colon cancer from Albanian patients
Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer
Randomized phase II study of cetuximab versus irinotecan and cetuximab in patients with chemo-refractory KRAS codon G13D metastatic colorectal cancer (G13D-study)
EGFR related mutational status and association to clinical outcome of third-line cetuximab-irinotecan in metastatic colorectal cancer
Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer
KRAS Status is Associated with Metabolic Parameters in Metastatic Colorectal Cancer According to Primary Tumour Location
Concordance of KRAS/BRAF Mutation Status in Metastatic Colorectal Cancer before and after Anti-EGFR Therapy
Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan
KRAS induces lung tumorigenesis through microRNAs modulation
Author Correction: Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer
Characterizing MRI features of rectal cancers with different KRAS status
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial